| 1 |
The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials |
|
|
| Ida Brandt Andersen,Mikkel Andreassen,Jesper Krogh |
|
| Diabetes, Obesity and Metabolism. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model |
|
|
| Mary Courtney Moore,Marta S. Smith,Larry L. Swift,Anthony H. Cincotta,Michael Ezrokhi,Nicholas Cominos,Yahong Zhang,Ben Farmer,Alan D. Cherrington |
|
| American Journal of Physiology-Endocrinology and Metabolism. 2020; 319(1): E133 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus |
|
|
| Maka Siamashvili,Stephen Davis |
|
| Expert Opinion on Pharmacotherapy. 2020; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus |
|
|
| Stanley S. Schwartz,Farhad Zangeneh |
|
| Postgraduate Medicine. 2016; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters |
|
|
| E.M. Lamos,D.L. Levitt,K.M. Munir |
|
| Primary Care Diabetes. 2016; 10(1): 60 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases |
|
|
| Alexander O Shpakov,Kira V Derkach,Lev M Berstein |
|
| Future Science OA. 2015; 1(3) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Bromocriptine mesylate QR in treatment of Type 2 diabetes |
|
|
| George Grunberger |
|
| Diabetes Management. 2014; 4(2): 203 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
A review of the efficacy and safety of oral antidiabetic drugs |
|
|
| Stephanie Aleskow Stein,Elizabeth Mary Lamos,Stephen N Davis |
|
| Expert Opinion on Drug Safety. 2013; 12(2): 153 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
